TMOHealthcare · Diagnostics & ResearchThe 27 Wall Street analysts covering Thermo Fisher Scientific, Inc. hold a median 12-month price target of $750 — +5.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Thermo Fisher Scientific, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TMO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.8% from it.
Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Citigroup | Maintains | Buy | $685 → $800 |
| 22 Oct 2026 | Baird | Maintains | Outperform | $723 → $756 |
| 22 Oct 2026 | Barclays | Maintains | Overweight | $750 → $775 |
| 22 Oct 2026 | RBC Capital | Maintains | Sector Perform | $580 → $730 |
| 22 Oct 2026 | Stifel | Maintains | Buy | $650 → $775 |
| 22 Oct 2026 | TD Cowen | Maintains | Buy | $760 → $810 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $650 → $730 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | — |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | — |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $675 → $760 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | — |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $650 → $750 |
| 9 Sept 2026 | UBS | Assumes | Buy | $540 → $730 |
| 3 Sept 2026 | CLSA | Initiates | Outperform | — |
| 3 Sept 2026 | CLSA | Initiates | Outperform | $748 |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | $620 → $650 |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 27 July 2026 | Piper Sandler | Maintains | Neutral | — |
| 27 July 2026 | Piper Sandler | Maintains | Neutral | $510 → $600 |
| 24 July 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TMO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Thermo Fisher Scientific, Inc. returned +27.5% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 22% of US stocks
Cheaper than 21% of US stocks
Cheaper than 11% of US stocks
Higher than 51% of US stocks
Higher than 44% of US stocks
Higher than 50% of US stocks
Higher than 79% of US stocks
Higher than 77% of US stocks
Higher than 71% of US stocks
Higher than 78% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Thermo Fisher Scientific, Inc. has a market value of $260.4B and an enterprise value of $296.0B.
Revenue in the twelve months to 30 June 2026: $46.3B. The latest quarter grew 9.1% year on year.
Net income over the same four quarters: $7.0B, a 15.1% net margin.
Diluted earnings per share, trailing twelve months: $18.59.
Free cash flow in the twelve months to 30 June 2026: $7.3B.
Thermo Fisher Scientific, Inc. spent $5.0B on share buybacks and $662.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 37.1×; forward P/E: 25.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.27%, paying out 10% of earnings.
Thermo Fisher Scientific, Inc. employs 125,000 people — $371K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Thermo Fisher Scientific, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Parnassus Value Equity Fund (Investor Shares) returned -1.38% net of fees in the quarter, trailing the Russell 1000 Value Index's 2.61% return. Thermo Fisher was listed among the fund’s top contributors.
Why it matters — Thermo Fisher’s inclusion among the fund’s top contributors indicates it aided the portfolio’s performance during the quarter.
The excerpt reports that TMO’s organic growth was 5%, 200 basis points above consensus, and that management raised full-year organic growth guidance. It also notes sales and guidance updates for MTD and TEVA.
Why it matters — TMO watchers may note the company’s reported growth exceeded consensus and its full-year organic growth guidance was raised.
Thermo Fisher reported 6% organic growth in Q3, with sales and EPS above expectations, and raised its full-year guidance. Growth was supported by demand in clinical research, bioproduction, and electron microscopy, while operating margin reached 24.5%.
Why it matters — The results highlight ongoing growth across several business areas and a higher full-year outlook for TMO.
Thermo Fisher raised its 2026 organic revenue growth outlook to 4%. Third-quarter revenue was $12.14 billion, with 6% organic growth.
Why it matters — The updated outlook and quarterly revenue growth provide TMO watchers with information on the company’s recent performance and expectations.
Thermo Fisher Scientific reported upbeat third-quarter results and raised its FY2026 forecast, according to the excerpt.
Why it matters — TMO watchers may note the company’s positive earnings update and higher full-year forecast.
The 27 Wall Street analysts covering Thermo Fisher Scientific, Inc. have a median 12-month price target of $750, with estimates ranging from $560 to $830. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Thermo Fisher Scientific, Inc., 23 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Thermo Fisher Scientific, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +5.8% from the last close, and Ticker Nerd's factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Thermo Fisher Scientific, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $560 to $830 over the next 12 months.
Thermo Fisher Scientific, Inc. returned +27.5% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Thermo Fisher Scientific Inc. is a global life sciences and laboratory technology company providing products, services, and specialized expertise that support scientific research, clinical diagnostics, pharmaceutical development, and biopharmaceutical manufacturing.
The most recent item we track (Seeking Alpha, 27 Oct 2026): "Parnassus Value Equity Fund Q3 2026 Portfolio Review". Parnassus Value Equity Fund (Investor Shares) returned -1.38% net of fees in the quarter, trailing the Russell 1000 Value Index's 2.61% return. Thermo Fisher was listed among the fund’s top contributors.
Thermo Fisher Scientific Inc. is a global life sciences and laboratory technology company providing products, services, and specialized expertise that support scientific research, clinical diagnostics, pharmaceutical development, and biopharmaceutical manufacturing. Its portfolio includes analytical instruments, laboratory equipment, research reagents, consumables, genetic analysis tools, and specialty diagnostic products used to identify and monitor diseases. The company also provides laboratory services, clinical research support, bioprocessing solutions, and contract development and manufacturing services for pharmaceutical and biotechnology organizations. Thermo Fisher Scientific Inc. serves academic institutions, hospitals, government laboratories, pharmaceutical companies, biotechnology firms, and industrial researchers across international markets. Its operations span analytical technologies, specialty diagnostics, life science solutions, and laboratory products and services. By combining instruments, consumables, digital capabilities, and outsourced laboratory expertise, the company supports workflows ranging from basic research and drug discovery to clinical testing, quality control, and commercial-scale biomanufacturing. This broad operating profile gives Thermo Fisher Scientific Inc. a significant role in the infrastructure of modern healthcare, life sciences, and scientific research.
CEO Mr. Marc N. Casper · 125,000 employees · United States · https://www.thermofisher.com
